相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。US Renal Data System 2012 Annual Data Report
Allan J. Collins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Hypotension and ischaemic stroke associated with aliskiren in the ALTITUDE trial: Sensitisation of the Bezold-Jarisch reflex?
Peter Sever
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2013)
Improving the efficacy of RAAS blockade in patients with chronic kidney disease
Hiddo J. Lambers Heerspink et al.
NATURE REVIEWS NEPHROLOGY (2013)
Dual RAS blockade-controversy resolved REPLY
Piero Ruggenenti et al.
NATURE REVIEWS NEPHROLOGY (2013)
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases
Enrique Morales et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
ACE2, angiotensin-(1-7), and Mas: the other side of the coin
Michael Bader
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2013)
Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature - preventable causes of AKI and SORO-ESRD - a call for re-engineering of nephrology practice paradigms
Macaulay A. C. Onuigbo
RENAL FAILURE (2013)
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
D. Di Raimondo et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
SM-368229, a Novel Promising Mineralocorticoid Receptor Antagonist, Shows Antihypertensive Efficacy With Minimal Effect on Serum Potassium Level in Rats
Tetsuro Nariai et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers
Hiddo J. Lambers Heerspink et al.
KIDNEY INTERNATIONAL (2012)
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy
Sara S. Roscioni et al.
NATURE REVIEWS NEPHROLOGY (2012)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
David A. Calhoun et al.
CIRCULATION (2011)
Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy
Frederik Persson et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Femke Waanders et al.
CURRENT VASCULAR PHARMACOLOGY (2011)
Initial Angiotensin Receptor Blockade-Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria A post hoc analysis of the IRMA-2 trial
Merel E. Hellemons et al.
DIABETES CARE (2011)
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Y. Miao et al.
DIABETOLOGIA (2011)
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
E. Imai et al.
DIABETOLOGIA (2011)
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2011)
Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial
Yan Miao et al.
HYPERTENSION (2011)
SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity
Tetsuro Nariai et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2011)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp et al.
KIDNEY INTERNATIONAL (2011)
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Hermann Haller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
Maartje C. J. Slagman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease
Helmy M. Siragy et al.
AMERICAN JOURNAL OF NEPHROLOGY (2010)
Aldosterone Synthase Inhibition With LCI699 A Proof-of-Concept Study in Patients With Primary Aldosteronism
Laurence Amar et al.
HYPERTENSION (2010)
The Biology of the (Pro)Renin Receptor
Genevieve Nguyen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria
Bruce A. Perkins et al.
KIDNEY INTERNATIONAL (2010)
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Piero Ruggenenti et al.
NATURE REVIEWS NEPHROLOGY (2010)
Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function
Maartje C. J. Slagman et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Systolic Heart Failure
John J. V. McMurray
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD
Macaulay A. C. Onuigbo
RENAL FAILURE (2010)
Aldosterone and inflammation
Kimberly C. Gilbert et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)
Linda F. Fried et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
Frederik Persson et al.
DIABETES CARE (2009)
Dual Renin-Angiotensin System Blockade and Kidney Disease
Hans-Henrik Parving et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
Uzma F. Mehdi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
William B. Lea et al.
KIDNEY INTERNATIONAL (2009)
Is the ONTARGET renal substudy actually off target?
Piero Ruggenenti et al.
NATURE REVIEWS NEPHROLOGY (2009)
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes.
Michael Mauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease
Regina Kunz et al.
ANNALS OF INTERNAL MEDICINE (2008)
Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications
Maria F. Lopes-Virella et al.
DIABETES CARE (2008)
Diabetic nephropathy: Mechanisms of renal disease progression
Yashpal S. Kanwar et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2008)
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
Liffert Vogt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes
A. Mohanram et al.
KIDNEY INTERNATIONAL (2008)
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
F. Persson et al.
KIDNEY INTERNATIONAL (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Radiographic Contrast-Induced Nephropathy and Patient Mortality
Macaulay A. C. Onuigbo
MAYO CLINIC PROCEEDINGS (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis
M. A. C. Onuigbo et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2008)
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats
D. J. Kelly et al.
DIABETOLOGIA (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel et al.
LANCET (2007)
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
Hirofumi Makino et al.
DIABETES CARE (2007)
Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A Randomized controlled study of benazepril and losartan in chronic renal insufficiency
Fan Fan Hou et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Wouter B. A. Eijkelkamp et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
The incidence and implications of aldosterone breakthrough
Andrew S. Bomback et al.
NATURE CLINICAL PRACTICE NEPHROLOGY (2007)
Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes
Minghao Ye et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function
Anton H. van den Meiracker et al.
JOURNAL OF HYPERTENSION (2006)
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
Murray Epstein et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells
Z. Su et al.
KIDNEY INTERNATIONAL (2006)
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy:: A post hoc analysis of RENAAL
D de Zeeuw et al.
KIDNEY INTERNATIONAL (2006)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes - A meta-analysis of randomized clinical trials
H Abuissa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
K Rossing et al.
KIDNEY INTERNATIONAL (2005)
Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
S Bianchi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
G Giacchetti et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2005)
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy
RC Atkins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Diabetic nephropathy: Diagnosis, prevention, and treatment
JL Gross et al.
DIABETES CARE (2005)
The regulation of aldosterone synthase expression
MH Bassett et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2004)
Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats:: influence of salt
C Richer-Giudicelli et al.
JOURNAL OF HYPERTENSION (2004)
Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells
ML Tuck et al.
JOURNAL OF HYPERTENSION (2004)
From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines
BF Schrijvers et al.
ENDOCRINE REVIEWS (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
AH Barnett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preventing microalbuminuria in type 2 diabetes
P Ruggenenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
KJ Schjoedt et al.
DIABETOLOGIA (2004)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
D de Zeeuw et al.
KIDNEY INTERNATIONAL (2004)
Angiotensin II receptor blockade - Is there truly a benefit of adding an ACE inhibitor?
A Forclaz et al.
HYPERTENSION (2003)
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
AI Adler et al.
KIDNEY INTERNATIONAL (2003)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
WC Knowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Ramipril and the development of diabetes
S Yusuf et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
M Epstein
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
Marked suppression of renin levels by β-receptor blocker in patients treated with standard heart failure therapy:: a potential mechanism of benefit from β-blockade
SR Holmer et al.
JOURNAL OF INTERNAL MEDICINE (2001)
Preserving renal function in adults with hypertension and diabetes: A consensus approach
GL Bakris et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
Y Lacourcière et al.
KIDNEY INTERNATIONAL (2000)
Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function
P van Paassen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2000)
分享论文
